Introduction
Despite significant improvements in treatment, about 20% of children with acute lymphoblastic leukaemia (ALL) still suffer from relapse (1) (2) (3) (4) (5) . Unfortunately the cure rate remains low with event-free survival (EFS) reaching only 30% at 10 years after relapse (6) (7) (8) (9) .
Few prognostic factors have been identified (10) . Blast phenotype (T versus B), site of relapse, and duration of the first remission are the main variables affecting outcome. The current relapse risk group stratifications are based on the system first described by the BerlinFrankfurt-Munster (BFM) relapse group, which takes into account the time of relapse, the site of relapse (bone marrow and/or extramedullar), and the subsequent immunophenotype to categorize patients into one of four risk categories (S1 to S4) (11) . This stratification has been adapted by the Medical Research Council (MRC, UK) and is also used by the Children's Oncology Group which divided marrow relapse into early relapse occurring up to 36 months from diagnosis and late relapse which occurred greater than or equal to 36 months from initial diagnosis (7, 8) . The Children's Cancer Group has also divided relapses into early (< 18 months from diagnosis), intermediate (18-35 months) and late relapse (≥36 months) (12) .
In this context, ETV6/RUNX1-positive ALLs have a separate status. Indeed, the ALL subgroup is characterized by a good prognosis which is better than for B-ALL without this fusion transcript (2) (3) (4) (5) 13) . Nevertheless, some recent long-term results revealed late relapses in this group of patients (14, 15) . It has been hypothesized that a relapse is essentially a de novo ALL originating from a preleukemic stem cell (16) (17) (18) (19) . This notion should be taken into account when considering the treatment options. The increased proportion of extramedullary relapses including testicular or ovarian relapses has also been discussed by a few authors (20, 21) . To investigate the outcome of ETV6/RUNX1-positive ALL relapses, we report the longterm results of the ETV6/RUNX1-positive ALL relapses initially enrolled into the FRALLE93 protocol and we identify some prognostic factors which call into question the current therapeutic approach for treating late relapses.
Design and Methods
The FRALLE (FRench group for childhood ALL) 93 
Statistical analysis
Summary statistics were calculated, namely median (inter-quartile range, IQR) for continuous variables, and frequency (with percentages) for qualitative variables.
Distribution of qualitative variables was compared with the chisquare test, or -when inappropriate-the Fisher exact test; comparison of continuous variables was based on the nonparametric Wilcoxon rank-sum test.
We first compared the characteristics of tested and non-tested patients, to check for potential selection bias. We then focused on the ETV6/RUNX1 positive children who relapsed. We compared the cumulative incidence of relapse in positive versus negative patients. Relapses were segregated into isolated central nervous system (CNS) relapse, isolated bone-marrow relapse, and others. We also considered bone-marrow relapses (whether isolated or combined), as well as testicular relapses, the latter only assessed in boys.
Finally, we focused on the outcome of ETV6/RUNX1-positive compared with negative patients. Relapsed patients were classified according to the risk groups defined in the REZ-BFM 95/96 study (11) . This distinguished S1/S2 patients (isolated bone-marrow relapses occurring ≥6 months after completion of primary therapy, isolated extra-medullary relapses, and combined bone marrow relapses occurring ≥ 18 months after completion of primary therapy) from S3/S4 patients (<6 months isolated bone marrow relapses and < 18 months after primary diagnosis combined bone marrow relapses).
Patient follow-up data were updated in October, 2010. The cumulative incidence of relapse was estimated from the date of complete remission, with death prior to relapse considered as a competing risk, and subgroup comparisons based on the Gray test. The Kaplan-Meier method was used to estimate the overall survival (OS) probabilities with 95% confidence intervals (CI) from the date of relapse until death, irrespective of cause. Comparisons of Kaplan-Meier curves were based on the log-rank test. Multivariate Cox stepwise forward-regression analysis (including testicular and non-testicular relapses) was performed to determine the independent set of prognostic variables.
All statistical tests were two-sided, with p-values of 0.05 or less denoting statistical significance. Statistical analysis was performed using the software SAS v9.2 (SAS Inc, Cary, NC), and R 2.10.1 (http://www.R-project.org) software packages.
Results

Total cohort
A flow chart representing the study design is shown in Figure 1 . Among the 1,105 B lineage ALL excluding infants and patients with t (9;22) or t (4;11), 724 had a known ETV6/RUNX1 status (most of the other cases were diagnosed before systematic screening). In terms of age, gender, blood prednisone response, day 21 marrow status, complete remission, and survival, there were no differences between these 724 patients and the 381 who were not tested for ETV6/RUNX1. However, the initial median leukocyte count was higher in the tested group (10.10 9 /l versus 6.4.10 9 /l p= 0.003), and more patients were enrolled in the low-risk group of treatment among those not tested for ETV6/RUNX1 ALL (22% versus 13% p=0.001).
Tested patients
A total of 186 (97.4%) out the 191 patients with t(12;21) achieved CR1, whereas 6 (1.1%) out of the 533 ETV6/RUNX1-negative patients did not achieve CR1 (p= 0.17).
Median follow-up after CR was 9.9 years [IQR: 8. cases), we distinguished the 5-year cumulative incidence of relapse in males and females. As depicting in Figure 2B 
ETV6/RUNX1-positive ALL relapses
The initial clinical features of the 43 ETV6/RUNX1-positive ALL relapses are shown in Table   1 
Salvage therapy after relapse
According to the risk groups defined by the REZ-BFM 95/96 study, 35 (81.4%) patients were classified as S1/S2 and 8 (18.6%) patients were classified as S3/S4.
All but three patients received a second-line therapy protocol (three patients were treated according to a first-line protocol after a relapse occurring at 68, 39, and 32 months after diagnosis). Thirty-seven patients were included in the COOPRALL-97 study (23) which recommended a VANDA (VP-16, cytarabine, mitoxantrone, dexamethasone, asparaginase) induction regimen (except for the late extra-medullary relapses) followed by successive blocks (B1, B2, B3). If an HLA identical donor was available, stem cell transplantation (SCT) was performed after 2 or 3 blocks. Otherwise, alternative treatment consisted of 3 successive blocks repeated 3 times followed by autologous transplantation or -for late combined/isolated medullary or isolated extra medullary relapses-maintenance and CNS radiotherapy. Two patients were treated according to a Capizzi scheme (24) and the latest one according to the UKALL R2 (8) .
Outcomes
Median follow-up after relapse was 7.7 years [IQR: 6.2-9], with only 1 child lost to follow-up at 12 months after first relapse.
All but one patient (due to early death) achieved CR2 (n=42, 98% 
Prognostic factors
Based on univariate analyses, the overall survival of ETV6/RUNX1-positive ALL after relapse was significantly affected by the duration of the first remission with a 5-year OS rate that was significantly better when relapse occurred after 36 months (80.8%, 95%CI:66.9-97.5% versus 31.2%, 95%CI:15.1-64.6%, p=0.0008). Female gender was also associated with a poor survival (p= 0.015), whereas the site of relapse (p= 0.13), age at initial diagnosis (p= 0.81), and leukocytosis (p=0.42) were all not found to be of any prognostic value (Table 2) .
Similarly, the consolidation strategy (allograft or chemotherapy ± autograft) had no affect on survival (p=0.18).
In multivariate Cox-regression analysis, only the duration of first remission remained associated with the outcome ( Figure 4A ). In particular, the site of relapse (testicular versus non-testicular relapse) did not provide any additional prognostic information (p=0.79).
Although timing of relapse of ETV6/RUNX1-negative patients impacted also significantly prognosis ( Figure 4B ), the 5-year OS rate of the 73 tested patients who relapsed after 36 months appeared to be significantly different in the 27 ETV6/RUNX1-positive patients (4 extra-medullary, 9 combined and 14 isolated marrow relapses) compared to the 46 ETV6/RUNX1-negative ones (81% versus 50%, respectively; p= 0.015 by the log-rank test).
Discussion
After a long-term follow-up, we have reported here the results of the ETV6/RUNX1-positive ALL relapses which were initially enrolled in the FRALLE 93 protocol. Indeed, long-term results are now mandatory because very late relapses have been reported (20, 21) .
In agreement with previous studies, we found that relapses occurred in about 20 % of ETV6/RUNX1-positive ALL, and for males after a longer remission period than other ALL of B lineage (13, 15, 25, 26, 27) . Indeed, the male cumulative incidence of relapses was (13, 15) , and here we reported a similar good overall outcome of 62.1 % which is significantly better than ETV6/RUNX1-negative relapses. We also found that almost 98% of patients achieved a second complete remission which is significantly higher than that reported by the ALL-REZ BFM 90 and the MRC UKALL-R (6, 9) and also higher than FRALLE 93 ETV6/RUNX1-negative relapses.
Unfortunately, in our retrospective study, we were unable to explore IgH/TCR rearrangements or sequence the ETV6/RUNX1 genome to better understand treatment failures.
The respective prognostic role of age, site, and time of relapse in the outcome of all types of relapses has been often debated (9, 12) . In addition, the definition of extramedullary relapses could, in an early date, move considering the prognostic relevance of submicroscopic bone marrow involvement based on in vitro amplification sensitive methods (30). Age did not affect prognosis in our exclusively pediatric study but it should be noted that ETV6/RUNX1-positive ALL can present a different clinical progress in young adults (14) . We showed that only time-point of relapse had prognostic significance in a multivariate analysis for ETV6/RUNX1 relapses. We thus highlight that the outcome of relapses occurring ≥36 months reached an OS rate of 80.8% which is excellent and similar to the prognosis of primary ALL.
We could not show any contribution of the high incidence of testicular relapse to this very favourable outcome, possibly due to some lack of statistical power. In contrast, the prognosis of early recurrences (stratified as S3/S4 according to ALL REZ-BFM classification) remained poor despite the presence ETV6/RUNX1 positivity. This timing of relapse is also significant for ETV6/RUNX1-negative relapses but not reaching such a high OS for late relapses. This finding may support the hypothesis that the majority of ETV6/RUNX1 "late" relapses could be 
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